Security key
492327101
Keros Therapeutics, Inc. - Common Stock (KROS)
CUSIP: 492327101
Q3 2020 13F Holders as of 30 Sep 2020
- Security type / class
- Equity / Common Stock
- Total 13F shares
- 11,780,724
- Total 13F value
- $454,579,430
- Share change
- +854,561
- SEC-reported price per share
- $38.57
- Number of holders
- 49
- Value change
- +$33,779,230
- Number of buys
- 23
- Number of sells
- 23
- Shares outstanding
- 19,932,637
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q3 2020
Institutions
49
Top holders
10
KROS full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q3 2026
Keros Therapeutics, Inc. SEC filings
Keros Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 492327101
Recent filing periods:
Ownership snapshot
Top reported holders of KROS - Keros Therapeutics, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
RA CAPITAL MANAGEMENT, L.P.
Disclosed value leader
RA CAPITAL MANAGEMENT, L.P.
Comparable rows
0/15
Latest evidence
30 Jun 2020
13F
Highest disclosed value: $70,331,000
15 rows are not safely comparable across share classes.
Showing 1-6 of 15 holder rows.
Quick read
RA CAPITAL MANAGEMENT, L.P. has the largest disclosed position value at $70.33M.
0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens RA CAPITAL MANAGEMENT, L.P.'s linked filing trail.
Disclosed position value
Top 5
RA CAPITAL MANAGEMENT, L.P.
$70.33M
ORBIMED ADVISORS LLC
$63M
Foresite Capital Management IV, LLC
$53.57M
FMR LLC
$51M
Venrock Adviser, LLC
$25.22M
Value bars compare disclosed positions; verify each figure against the linked filing evidence.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. |
13F
Company
|
—
denominator unverified
|
$70,331,000
1,875,000 shares
|
— | 30 Jun 2020 |
| ORBIMED ADVISORS LLC |
13F
Company
|
—
denominator unverified
|
$62,995,000
1,679,417 shares
|
— | 30 Jun 2020 |
| Foresite Capital Management IV, LLC |
13F
Company
|
—
denominator unverified
|
$53,567,000
1,428,071 shares
|
— | 30 Jun 2020 |
| FMR LLC |
13F
Company
|
—
denominator unverified
|
$51,001,000
1,359,672 shares
|
— | 30 Jun 2020 |
| Venrock Adviser, LLC |
13F
Company
|
—
denominator unverified
|
$25,218,000
672,306 shares
|
— | 30 Jun 2020 |
| BlackRock Finance, Inc. |
13F
Company
|
—
denominator unverified
|
$24,769,000
660,321 shares
|
— | 30 Jun 2020 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q3 2020
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
49
Shares
11,780,724
Rows available
49
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q3 2020 vs Q2 2020 Across Filers
Q2 2020 holders
51
Q3 2020 holders
49
Holder diff
-2
| Investor | Q2 2020 Shares | Q3 2020 Shares | Share Diff | Share Chg % | Q2 2020 value | Q3 2020 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend